PTPRF and pancreatic neoplasm: These novel drug associations that target the heterogeneous pancreatic tumour, including SOM230-LAR, or novel protein synthesis inhibitors, together with a chemotherapeutic drug should provide promising therapeutic benefits for PDAC patients.